Back to Top Skip to main content

WRAIR begins Phase 1 clinical trial of Marburg vaccine

The WRAIR study evaluates the VRC-MARADC087-00-VP vaccine, developed by the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. (U.S. Army file photo) The WRAIR study evaluates the VRC-MARADC087-00-VP vaccine, developed by the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. (U.S. Army file photo)

Recommended Content:

Immunization Healthcare | Immunizations

SILVER SPRING, Md. — The Walter Reed Army Institute of Research (WRAIR) recently administered the first vaccine in a Phase 1 clinical trial to evaluate the safety and immunogenicity of a Marburg vaccine candidate in healthy adult volunteers.

The WRAIR study evaluates the VRC-MARADC087-00-VP vaccine, developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The recombinant chimpanzee adenovirus type 3-vectored Marburg virus vaccine candidate being tested is aimed at stimulating rapid but durable immunity. This vaccination strategy is considered optimal to protect both first-line health workers and general populations in areas where outbreaks occur.

“Given the recent deadly outbreak of Marburg virus in Uganda, there is a critical need to develop a safe and effective vaccine which has the potential to protect our soldiers and the public from this serious threat,” said Army Lt. Col. Melinda Hamer, Chief of the WRAIR Clinical Trials Center in Silver Spring, Maryland, where the trial is being conducted.

Forty healthy, adult volunteers will be enrolled and assigned into one of two groups to evaluate different vaccine dosages. Volunteers will be closely followed over the course of approximately one year after vaccination for safety and immune system response.

The Marburg virus is in the same family as Ebola and causes severe hemorrhagic fever in humans. Case fatality rates in Marburg outbreaks have ranged from 24% to 88%. The most recent outbreak occurred in Uganda in 2017.

WRAIR conducted the first Ebola vaccine clinical trial in Africa in 2009, testing an early vaccine candidate also developed by the VRC at NIAID. During the 2014 West Africa Ebola outbreak, WRAIR conceived of, and then initiated a Phase I clinical trial of the VSV-EBOV vaccine candidate over a period of just 11 weeks at its CTC. WRAIR has conducted six Ebola vaccine studies to date.

“This first-in-human trial of the NIH vaccine is part of an important inter-agency effort by the US government to anticipate and counter emerging infectious threats to the Americans, both military and civilian, at home and abroad,” added Dr. Kayvon Modjarrad, the Director of the Emerging Infectious Diseases Branch at WRAIR.

You also may be interested in...

Vaccination is the best defense against the flu

Article
12/10/2018
Vaccination is the primary method for preventing influenza and its complications and getting an annual influenza vaccine is the best way to protect yourself and your family from the flu. (U.S. Army photo by Staff Sgt. Erica Knight)

Vaccination is needed every year because the Influenza viruses change

Recommended Content:

Health Readiness | Immunization Healthcare | Immunizations

Global Routine Vaccination Coverage — 2017

Report
11/16/2018

Global coverage with vaccines to prevent diphtheria, tetanus, pertussis, polio, and measles has remained at 84%–85% since 2010. Prioritizing countries with the highest number of unvaccinated children to implement context-specific strategies has the potential to increase immunization coverage globally.

Recommended Content:

Immunization Healthcare | Measles-Mumps-Rubella | Polio | Tetanus-Diphtheria-Pertussis

Updated Framework for Development of Evidence-Based Recommendations by the Advisory Committee on Immunization Practices

Report
11/16/2018

In 2010, the Advisory Committee on Immunization Practices (ACIP) implemented the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for developing evidence-based recommendations. Since its February 2018 meeting, ACIP has incorporated the use of Evidence to Decision or Evidence to Recommendation (EtR) frameworks into GRADE methodology.

Recommended Content:

Immunization Healthcare | Vaccine Recommendations

General Best Practice Guidelines for Immunization

Publication
10/30/2018

The Centers for Disease Control and Prevention (CDC) recommends routine vaccination to prevent 17 vaccine-preventable diseases that occur in infants, children, adolescents, or adults. This report provides information for clinicians and other health care providers about concerns that commonly arise when vaccinating persons of various ages.

Recommended Content:

Immunization Healthcare | Vaccine Recommendations | Continuous Quality Immunization Improvement Process (CQIIP) and Virtual Continuous Quality Immunization Improvement Process (VCQIIP)

Immunization Tool Kit 9th Edition

Publication
10/25/2018

A practical reference that facilitates and enhances the global delivery of quality immunization healthcare to Department of Defense (DoD) beneficiaries and employees. The Defense Health Agency Immunization Healthcare Branch (DHA-IHB) publishes the Immunization Tool Kit based on national recommendations, evidenced-based, peer-reviewed published medical ...

Recommended Content:

Immunization Healthcare

Vaccination Coverage Among Children Aged 19–35 Months — United States, 2017

Report
10/12/2018

The Advisory Committee on Immunization Practices recommends routine vaccination by age 24 months against 14 potentially serious illnesses. In 2017, coverage with most recommended vaccines among children aged 19–35 months remained stable and high but was lower in more rural areas and among uninsured or Medicaid-insured children.

Recommended Content:

Immunization Healthcare | Vaccine-Preventable Diseases | Vaccine Schedules

Vaccination Coverage for Selected Vaccines and Exemption Rates Among Children in Kindergarten — United States, 2017–18 School Year

Report
10/12/2018

Immunization programs conduct annual kindergarten vaccination assessments to monitor school-entry vaccination coverage for all state-required vaccines. Median vaccination coverage was 94.3% for 2 doses of measles, mumps, and rubella vaccine; 95.1% for the state-required number of doses of diphtheria and tetanus toxoids and acellular pertussis vaccine; and 93.8% for 2 doses of varicella vaccine.

Recommended Content:

Immunization Healthcare | Vaccine-Preventable Diseases | Vaccine Schedules

Say ‘Shoo’ to the flu with TRICARE

Article
9/26/2018
Amanda LaFountain, a licensed practical nurse, administers the flu shot to a Soldier. (U.S. Army photo by Staff Sgt. Marshall Metzger)

Flu viruses are serious, contagious viruses that can lead to hospitalization or even death

Recommended Content:

Health Readiness | Immunization Healthcare | Public Health

Preparing for travel can prevent illness

Article
7/18/2018
Experts encourage overseas travelers to seek advice from a health care provider before leaving on a trip, and to make sure recommended vaccinations are up to date (U.S. Air Force photo by Tech. Sgt. De-Juan Haley)

Experts encourage travelers to be proactive about their travel medicine needs, including learning about the health risks associated with the destination and checking with their doctor to make sure they’re in good health

Recommended Content:

Health Readiness | Public Health | Immunizations | Summer Safety

Advice for healthy older adults: Get the new shingles vaccine

Article
3/29/2018
Navy Petty Officer 3rd Class Luis Echevarria draws up the new vaccine for shingles at Naval Hospital Jacksonville, Florida.  Shingrix is recommended for healthy adults 50 and older even if they’ve already had shingles or received the previous shingles vaccine. (U.S. Navy photo by Petty Officer 1st Class Jacob Sippel)

Rash can recur, cause long-term pain

Recommended Content:

Vaccine-Preventable Diseases | Immunization Healthcare

Immunization University and Project Immune Readiness Certificate Retrieval Instructions

Publication
2/14/2018

This document provides instructions for students to retrieve their certificates for Immunization University and Project Immune Readiness courses

Recommended Content:

Immunization Healthcare

Department of Defense Global, Laboratory-based Influenza Surveillance Program’s Influenza vaccine effectiveness estimates and surveillance trends, 2016 – 2017 Influenza Season

Infographic
2/5/2018
Each year, the Department of Defense (DoD) Global, Laboratory-based Influenza Surveillance Program performs surveillance for influenza among service members of the DoD and their dependent family members. In addition to routine surveillance, vaccine effectiveness (VE) studies are performed and results are shared with the Food and Drug Administration, Centers for Disease Control and Prevention, and the World Health Organization for vaccine evaluation. This report documents the annual surveillance trends for the 2016 – 2017 influenza season and the end-of-season VE results. The analysis was performed by the U.S. Air Force School of Aerospace Medicine Epidemiology Laboratory, and the DoD Influenza Surveillance Program staff at Wright-Patterson Air Force Base, OH. FINDINGS: A total of 5,555 specimens were tested from 84 locations: •	2,486 (44.7%) negative •	1,382 (24.9%) influenza A •	1,093 (19.7%) other respiratory pathogens •	443 (8.0%) influenza B •	151 (2.7%) co-infections The predominant influenza strain was A (H3N2), representing 73.8% of all circulating influenza. Pie chart displays this information. Graph showing the numbers and percentages of respiratory specimens positive for influenza viruses, and numbers of influenza viruses identified, by type, by surveillance week, Department of Defense healthcare beneficiaries, 2016 – 2017 influenza season displays. The vaccine effectiveness (VE) for this season was slightly lower than for the 2015 – 2016 season, which had a 63% (95% confidence interval: 53% - 71%) adjusted VE. The adjusted VE for the 2016 – 2017 season was 48% protective against all types of influenza.  Access the full report in the January 2018 MSMR (Vol. 25, No. 1). Go to: www.Health.mil/MSMR

This infographic documents the annual surveillance trends for the 2016 – 2017 influenza season and the end-of-season vaccine effectiveness.

Recommended Content:

Health Readiness | Armed Forces Health Surveillance Branch | Influenza Summary and Reports | Medical Surveillance Monthly Report | Influenza Seasonal | Immunizations | Vaccine-Preventable Diseases | Force Health Protection

Army Medicine in thick of war on antibiotic-resistant bacteria

Article
2/2/2018
This strain of antibiotic-resistant Staphylococcus aureus bacteria is magnified 50,000 times.

The Centers for Disease Control and Prevention calls antibiotic resistance one of the world's most pressing public health problems

Recommended Content:

Immunization Healthcare

Cold and influenza season is underway – and it’s nothing to ‘shake off’

Article
1/12/2018
Cold and flu season usually runs from October to March, and peaks between December and February. Young children, adults 65 years and older, pregnant women, and people with chronic medical conditions have a higher risk for complications. Military Health System experts encourage everyone to take steps to prevent these viral illnesses from spreading. (U.S. Army photo by photo by Rachel Larue)

Military Health System experts share advice on how to prevent, treat, and distinguish between these two viral illnesses

Recommended Content:

Health Readiness | Preventive Health | Immunizations | Children's Health

Antibiotics not the answer for common cold

Article
12/21/2017
Antibiotics should only be used to treat bacterial infections, not viral infections as they will not work against upper respiratory illnesses caused by viruses. (U.S. Air Force photo by Airman 1st Class Kenna Jackson)

Antibiotics should only be used to treat bacterial infections, not viral infections

Recommended Content:

Immunization Healthcare
<< < 1 2 3 4 5 > >> 
Showing results 1 - 15 Page 1 of 5

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing.. Download a PDF Reader or learn more about PDFs.